R2 Technologies
R2 Technologies
Independent company founded with Blossom Innovations, LLC and our lead investor partner, Pansend Life Sciences, LLC (life sciences subsidiary of HC2 Holdings, Inc.), along with a Series B commercialization round with strategic partner, Huadong Medicine Co., Ltd.
Spun off to commercialize a groundbreaking Blossom Innovation cryotherapeutic platform, R2 Technologies is poised to have a game-changing impact on aesthetic dermatology — a global, growing market currently valued at $22B.
Proprietary Cryomodulation™ Technology
Contact system:
Robotic spray system:
-
An FDA-cleared contact system indicated for the treatment of benign skin lesions
-
A first-in-world robotic spray system designed for overall skin lightening
Both technologies harness the science of Cryomodulation™ to pause melanin production in target melanocytes by precisely controlling time and temperature, reducing melanin production while maintaining melanocyte viability, all without the disadvantages commonly associated with comparable treatments. Results are clear in 1-2 months and sustain with a consistent skin protection regimen.
Expert leadership
Leading the launch is a seasoned leadership team with deep expertise in cryobiology and consumer branding experience – including CoolSculpting® and Fraxel® – and a world-class collective track record of success in aesthetics and beyond. To learn more, visit the homepage for R2 Technologies.
More groundbreaking advances are taking root
Inspired and guided by our SEED principles, we’re actively developing a remarkable range of disruptive innovations in dermatology and beyond. Check back soon or follow our News & Insights for the latest developments in our pipeline, companies, and dermatology market.
